Mucinous Adenocarcinoma of the Colon
19
0
0
10
Key Insights
Highlights
Success Rate
59% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
36.8%
7 terminated out of 19 trials
58.8%
-27.7% vs benchmark
11%
2 trials in Phase 3/4
60%
6 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (19)
Edrecolomab in Treating Patients With Stage II Colon Cancer
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors
Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver
Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy
Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer
Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery
Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer
A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer
Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer